Methotrexate plus tofacitinib for rheumatoid arthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, open-label, multicenter trial enrolling about 130 adults with moderate-to-severe primary rheumatoid arthritis whose synovial biopsy shows a myeloid-stromal pathotype. Participants are randomized to an intensive treatment arm receiving methotrexate plus tofacitinib or to a conventional arm receiving methotrexate alone, with clinical and imaging follow-up to compare outcomes. Trial enrollment is limited to patients identified by synovial immunopathology at three hospitals in Guangdong, China. The aim is to determine whether early intensified, pathology-guided therapy reduces progression and improves response compared with standard methotrexate care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients were diagnosed according to the 1987 American College of Rheumatology or 2010 American College of Rheumatology/European League Against Rheumatism criteria
* Patients had moderate or high disease activity
* Patients had a synovial biopsy and with a myeloid-stromal pathotype
* Patients with good compliance, willing to participate in this study and sign an informed consent form

Exclusion Criteria:

* Patient received conventional synthetic disease modifying anti-rheumatic drugs treatment in the first 12 weeks of randomization
* Patient received biologic agents treatment in the first 6 months of randomization
* Patient received Janus kinase inhibitor treatment before randomization
* Patient with serious diseases under control (such as diabetes), serious respiratory diseases, serious chronic gastrointestinal diseases (such as active or recurrent gastrointestinal ulcers), serious blood system diseases (such as aplastic anemia, myelodysplastic syndrome) or any disease that can cause hemolysis or erythrocyte instability (such as malaria, hemolytic anemia)
* Patients with moderate to severe congestive heart failure (New York Heart Association grade III or IV), or recent (within 6 months prior to screening) cerebrovascular accident, myocardial infarction, coronary stent implantation, or uncontrolled hypertension
* Patients with blood routine WBC\<4.0 × 109/L, and/or Hb\<90g/L, and/or Plt\<100 × 109/L during the screening period
* Patients with active chronic liver disease or abnormal liver function, AST, ALT, GGT, and TBIL are more than twice the upper limit of normal during the screening period
* Patients with estimated glomerular filtration rate \<30ml/min during screening period
* Patients with history of symptomatic herpes zoster infection (within the first 12 weeks of randomization), recurrent or disseminated (even if only once) herpes zoster or disseminated (even if only once) herpes simplex infection
* Chest X-ray or CT examination indicates active tuberculosis, or latent tuberculosis (T-SPOT or TB-IGRA positive) without prophylactic tuberculosis treatment for at least 4 weeks
* Patients woth hepatitis C virus ribonucleic acid (HCV-RNA) testing are higher than the lower limit of detection; Or positive for Treponema pallidum antibody (TP Ab); Or human immunodeficiency virus antibody (HIV Ab) positive during the selected period
* Patients with hepatitis B surface antigen positive without prophylactic antiviral treatment
* Patients with history of lymphoproliferative diseases, or possibly various signs or symptoms of lymphoproliferative diseases
* Patients with any active malignant tumors or history of malignant tumors within the first 5 years, except for skin squamous or basal cell carcinoma, cervical carcinoma in situ, or breast ductal carcinoma in situ that has been treated and considered cured
* Patients with history of thromboembolism, including deep vein thrombosis, pulmonary embolism, arterial thrombosis, etc., or high risk factors prone to thromboembolism (such as obesity, smoking, abnormal coagulation function, diabetes, long-term use of estrogen or use of compound hormonal contraceptives or hormone replacement therapy, long-term braking, etc., which are comprehensively judged by the investigator according to clinical evaluation)
* Patients with undergone major surgery within the first 4 weeks of randomization, or is expected to undergo major surgery after enrollment; Or a history of chronic pain that may affect the evaluation of the study; Or have received organ transplantation before
* Patients with history of mental illness, alcoholism, drug or other substance abuse
* Pregnant women, lactating women, and men or women who plan to conceive in the near future
* The researchers believe that there are any other factors that may affect the progress or evaluation of the results of this study

Where it's running

• Foshan Hopsital of Traditional Chinese Medicine
  Foshan, Guangdong, China Recruiting
• Sun Yat-sen Memorial Hospital
  Guangzhou, Guangdong, China Recruiting
• The Affiliated Panyu Central Hospital of Guangzhou Medical University
  Guangzhou, Guangdong, China Recruiting
• Pu Ning Shi Ren Ming Yi Yuan
  Jieyang, Guangdong, China Recruiting
• Shenshan Medical Central, Memorial Hospital of Sun Yat-sen University
  Shantou, Guangdong, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Heart event risk in people with moderate-to-severe rheumatoid arthritis taking tofacitinib plus a statin versus TNF inhibitors.

  This will test whether taking tofacitinib with a daily statin changes the rate of major heart problems in people 50 and older with moderate-to-severe rheumatoid arthritis and at least one cardiovascular risk factor.

  Recruiting Phase 4 Shaikh Zayed Hospital, Lahore · Lahore, Punjab Province · NCT07554820

• Oral methotrexate versus tofacitinib for chronic plaque psoriasis

  This trial will test whether oral methotrexate or tofacitinib works better for adults with moderate-to-severe chronic plaque psoriasis.

  Recruiting Early Phase 1 Lahore General Hospital · Lahore, Punjab Province · NCT07261306

• Combining telitacicept and tofacitinib for treating difficult rheumatoid arthritis

  This study tests if combining two medications, telitacicept and tofacitinib, can help adults with tough-to-treat rheumatoid arthritis feel better when other treatments haven't worked.

  Recruiting Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT06979271

• Optimizing methotrexate therapy for rheumatoid arthritis patients

  This study is testing whether giving methotrexate as a pill or an injection helps people with active rheumatoid arthritis feel better and respond to treatment more effectively.

  Recruiting Phase 4 Medical University of Vienna · Vienna, State of Vienna · NCT06649136

• Comparing targeted therapy with triple therapy for rheumatoid arthritis patients not responding to standard treatments

  This study is testing whether adding a targeted therapy to existing medications works better than using a combination of traditional drugs for people with rheumatoid arthritis who haven't felt better with standard treatments.

  Recruiting Phase 4 University Hospital, Strasbourg, France · Strasbourg · NCT02714634

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.